サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：乾癬性関節炎の世界市場 - 市場シェア、規模、動向、業界分析：投与経路別、薬剤クラス別、流通チャネル別、地域別、セグメント予測（2022年～2030年）
市場調査レポート
商品コード
1150066

乾癬性関節炎の世界市場 - 市場シェア、規模、動向、業界分析：投与経路別、薬剤クラス別、流通チャネル別、地域別、セグメント予測（2022年～2030年）

Psoriatic Arthritis Market Share, Size, Trends, Industry Analysis Report, By Route of Administration (Oral, Parenteral, Topical); By Drugs Class; By Distribution Channel; By Region; Segment Forecast, 2022 - 2030
出版日: | 発行: Polaris Market Research | ページ情報: 英文 114 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
乾癬性関節炎の世界市場 - 市場シェア、規模、動向、業界分析：投与経路別、薬剤クラス別、流通チャネル別、地域別、セグメント予測（2022年～2030年）
出版日: 2022年10月01日
発行: Polaris Market Research
ページ情報: 英文 114 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の乾癬性関節炎の市場規模は、2030年までに222億米ドルに達すると予測されています。

当レポートでは、世界の乾癬性関節炎市場について調査し、市場力学、セグメント別分析、地域分析、企業プロファイルなどの情報を提供しています。

目次

第1章 イントロダクション

  • レポートの説明
    • 調査目的
    • 市場範囲
    • 前提条件
  • 利害関係者

第2章 エグゼクティブサマリー

  • 市場のハイライト

第3章 調査手法

  • 概要
    • データマイニング
  • 情報源
    • 一次情報
    • 二次情報

第4章 世界の乾癬性関節炎市場の洞察

  • 乾癬性関節炎 - 業界のスナップショット
  • 乾癬性関節炎市場力学
    • 促進要因と機会
    • 抑制要因と課題
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 新規参入者の脅威
    • 買い手の交渉力
    • 代替品の脅威
    • 既存企業間の競争力
  • PESTEL分析
  • 乾癬性関節炎市場の業界動向
  • バリューチェーン分析
  • COVID-19影響分析

第5章 世界の乾癬性関節炎市場：薬剤クラス別

  • 主な調査結果
  • イントロダクション
    • 世界の乾癬性関節炎市場：薬剤クラス別（2018年～2030年）
  • 非ステロイド性抗炎症薬（NSAIDs）
    • 世界の乾癬性関節炎市場：非ステロイド性抗炎症薬（NSAIDs）別、地域別（2018年～2030年）
  • 非生物学的疾患修飾性抗リウマチ薬（DMARD）
    • 世界の乾癬性関節炎市場：非生物学的疾患修飾性抗リウマチ薬（DMARD）別、地域別（2018年～2030年）
  • 生物学的疾患修飾性抗リウマチ薬（DMARD）
    • 世界の乾癬性関節炎市場：生物学的疾患修飾性抗リウマチ薬（DMARD）別、地域別（2018年～2030年）
  • その他
    • 世界のその他の乾癬性関節炎市場：地域別（2018年～2030年）

第6章 世界の乾癬性関節炎市場：投与経路別

  • 主な調査結果
  • イントロダクション
    • 世界の乾癬性関節炎市場：投与経路別（2018年～2030年）
  • 経口
    • 世界の乾癬性関節炎市場：経口別、地域別（2018年～2030年）
  • 非経口
    • 世界の乾癬性関節炎市場：非経口別、地域別（2018年～2030年）
  • 局所
    • 世界の乾癬性関節炎市場：局所別、地域別（2018年～2030年）

第7章 世界の乾癬性関節炎市場：流通チャネル別

  • 主な調査結果
  • イントロダクション
    • 世界の乾癬性関節炎市場：流通チャネル別（2018年～2030年）
  • 病院薬局
    • 世界の乾癬性関節炎市場：病院薬局別、地域別（2018年～2030年）
  • 小売薬局
    • 世界の乾癬性関節炎市場：小売薬局別、地域別（2018年～2030年）
  • オンライン薬局
    • 世界の乾癬性関節炎市場：オンライン薬局別、地域別（2018年～2030年）

第8章 世界の乾癬性関節炎市場：地域別

  • 主な調査結果
  • イントロダクション
    • 乾癬性関節炎市場評価：地域別（2018年～2030年）
  • 北米
    • 薬剤クラス別（2018年～2030年）
    • 流通チャネル別（2018年～2030年）
    • 投与経路別（2018年～2030年）
    • 米国
    • カナダ
  • 欧州
    • 薬剤クラス別（2018年～2030年）
    • 流通チャネル別（2018年～2030年）
    • 投与経路別（2018年～2030年）
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
  • アジア太平洋
    • 薬剤クラス別（2018年～2030年）
    • 流通チャネル別（2018年～2030年）
    • 投与経路別（2018年～2030年）
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
  • 中東・アフリカ
    • 薬剤クラス別（2018年～2030年）
    • 流通チャネル別（2018年～2030年）
    • 投与経路別（2018年～2030年）
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
  • ラテンアメリカ
    • 薬剤クラス別（2018年～2030年）
    • 流通チャネル別（2018年～2030年）
    • 投与経路別（2018年～2030年）
    • メキシコ
    • ブラジル
    • アルゼンチン

第9章 競合情勢

  • 事業拡大と買収の分析
    • 事業拡大
    • 買収
  • パートナーシップ/協業/協定/展示会

第10章 企業プロファイル

  • AbbVie Inc
  • AstraZeneca PLC
  • Amgen Inc
  • Bausch Health Companies Inc
  • Bristol-Myers Squibb Company
  • Celgene Corp
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc
  • Novartis International AG
  • Pfizer, Inc.
  • UCB S.A
図表

List of Tables

  • Table 1 Global Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 2 Global Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 3 Global Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 4 Psoriatic Arthritis Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • Table 5 North America: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 6 North America: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 7 North America: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 8 U.S.: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 9 U.S.: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 10 U.S.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 11 Canada: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 12 Canada: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 13 Canada: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 14 Europe: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 15 Europe: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 16 Europe: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 17 UK: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 18 UK: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 19 UK: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 20 France: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 21 France: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 22 France: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 23 Germany: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 24 Germany: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 25 Germany: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 26 Italy: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 27 Italy: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 28 Italy: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 29 Spain: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 30 Spain: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 31 Spain: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 32 Netherlands: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 33 Netherlands: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 34 Netherlands: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 35 Russia: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 36 Russia: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 37 Russia: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 38 Asia Pacific: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 39 Asia Pacific: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 40 Asia Pacific: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 41 China: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 42 China: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 43 China: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 44 India: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 45 India: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 46 India: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 47 Malaysia: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 48 Malaysia: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 49 Malaysia: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 50 Japan: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 51 Japan: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 52 Japan: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 53 Indonesia: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 54 Indonesia: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 55 Indonesia: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 56 South Korea: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 57 South Korea: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 58 South Korea: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 59 Middle East & Africa: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 60 Middle East & Africa: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 61 Middle East & Africa: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 62 Saudi Arabia: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 63 Saudi Arabia: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 64 Saudi Arabia: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 65 UAE: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 66 UAE: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 67 UAE: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 68 Israel: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 69 Israel: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 70 Israel: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 71 South Africa: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 72 South Africa: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 73 South Africa: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 74 Latin America: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 75 Latin America: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 76 Latin America: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 77 Mexico: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 78 Mexico: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 79 Mexico: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 80 Brazil: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 81 Brazil: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 82 Brazil: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • Table 83 Argentina: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 84 Argentina: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • Table 85 Argentina: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)

List of Figures

Figure 1. Global Psoriatic Arthritis Market, 2018 - 2030 (USD Billion)

Figure 2. Integrated Ecosystem

Figure 3. Research Methodology: Top-Down & Bottom-Up Approach

Figure 4. Market by Geography

Figure 5. Porter's Five Forces

Figure 6. Market by Route Of Administration

Figure 7. Global Psoriatic Arthritis Market, by Route Of Administration, 2021 & 2030 (USD Billion)

Figure 8. Market by Drug Class

Figure 9. Global Psoriatic Arthritis Market, by Drug Class, 2021 & 2030 (USD Billion)

Figure 10. Market by Distribuation Channel

Figure 11. Global Psoriatic Arthritis Market, by Distribuation Channel, 2021 & 2030 (USD Billion)

Figure 12. Psoriatic Arthritis Market Assessment, By Geography, 2018 - 2030 (USD Billion)

Figure 13. Strategic Analysis - Psoriatic Arthritis Market

目次
Product Code: PM1346

The global psoriatic arthritis market size is expected to reach USD 22.20 billion by 2030, according to a new study by Polaris Market Research. The report "Psoriatic Arthritis Market Share, Size, Trends, Industry Analysis Report, By Route of Administration (Oral, Parenteral, Topical); By Drugs Class; By Distribution Channel; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Some of the main drivers of the market growth include hectic lifestyles that exceed the maximum immune system, a rapidly aging population, growth in psoriasis incidence, increasing incomes that make enormous biologic treatment options more inexpensive, and a rise in the incidence of product portfolio approvals.

For instance, In March 2019, AbbVie Inc. announced that the interleukin-23 (IL-23) receptor SKYRIZI (risankizumab) has already been authorized by the Japanese Department of Health, Labour, and Welfare (MHLW) for adult patients being treated with psoriatic arthritis, generalized suppurative psoriasis, erythema psoriasis, and rheumatic diseases who haven't responded well.

The need for PsA medications for treatment is expected to rise due to the rising prevalence of psoriatic arthritis, an autoimmune illness brought on by the body's immune system attacking the skin and joints. People who already have plaque psoriasis are more likely to develop the condition. About 30% of people with psoriasis go on to develop PsA, an inflammatory disorder that affects the joints, according to a study released by Celgene Corporation.

The expansion of the market is anticipated to be fueled by the rising number of medication approvals from regulatory agencies. For instance, In December 2019, Pfizer Inc. declared that the USFDA had authorized its Infliximab product type, a monoclonal antibody (mAb) against tumor necrosis factor, as a product to Remicade for the treatment of individuals with rheumatoid arthritis, ulcerative colitis, Crohn's disease, ankylosing psoriatic arthritis, psoriatic arthritis, and plaque.

Psoriatic Arthritis Market Report Highlights

The online pharmacies segment is anticipated to grow at a significant CAGR over the forecast period due to increased internet use around the world, the comfort of online shopping, and the numerous discounts that are available through pharmacy sites.

The non-steroidal anti-inflammatory medicine segment is anticipated to dominate the market for treating PsA soon by earning the maximum share owing to the demand for immunosuppressive medications, robust sales of currently available goods, and growth in the number of launches of attractive pipeline candidates.

Asia Pacific is anticipated to grow with the fastest CAGR over the forecast period. One of the critical aspects expected to stimulate the development of biological therapies for psoriasis in China is the increasing incidence of obesity. Smoking, excessive alcohol consumption, and the development of unhealthy lifestyles are expected to drive the market in this country.

The global players include AbbVie, Amgen, AstraZeneca, Bausch Health, and Bristol-Myers Squibb.

Polaris Market Research has segmented the psoriatic arthritis market report based on drug class, route of administration, distribution channel, and region:

Psoriatic Arthritis, Drug Class Outlook (Revenue - USD Billion, 2018 - 2030)

Non-steroidal Anti-inflammatory Drugs (NSAIDs)

Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)

Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)

Others

Psoriatic Arthritis, Route Of Administration Outlook (Revenue - USD Billion, 2018 - 2030)

Oral

Parenteral

Topical

Psoriatic Arthritis, Distribution Channel Outlook (Revenue - USD Billion, 2018 - 2030)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Psoriatic Arthritis, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Psoriatic Arthritis Market Insights

  • 4.1. Psoriatic Arthritis - Industry Snapshot
  • 4.2. Psoriatic Arthritis Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rise in prevalence of psoriatic arthritis to fuel market growth
      • 4.2.1.2. Presence of a strong pipeline of drug to spur market growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Stringent regulations
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Psoriatic Arthritis Market Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Psoriatic Arthritis Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • 5.3. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
    • 5.3.1. Global Psoriatic Arthritis Market, by Non-steroidal Anti-inflammatory Drugs (NSAIDS), by Region, 2018 - 2030 (USD Billion)
  • 5.4. Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
    • 5.4.1. Global Psoriatic Arthritis Market, by Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), by Region, 2018 - 2030 (USD Billion)
  • 5.5. Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
    • 5.5.1. Global Psoriatic Arthritis Market, by Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), by Region, 2018 - 2030 (USD Billion)
  • 5.6. Others
    • 5.6.1. Global Other Psoriatic Arthritis Market, by Region, 2018 - 2030 (USD Billion)

6. Global Psoriatic Arthritis Market, by Route Of Administration

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • 6.3. Oral
    • 6.3.1. Global Psoriatic Arthritis Market, by Oral, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Parenteral
    • 6.4.1. Global Psoriatic Arthritis Market, by Parenteral, by Region, 2018 - 2030 (USD Billion)
  • 6.5. Topical
    • 6.5.1. Global Psoriatic Arthritis Market, by Topical, by Region, 2018 - 2030 (USD Billion)

7. Global Psoriatic Arthritis Market, by Distribuation Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Psoriatic Arthritis Market, by Hospital Pharmacies, by Region, 2018 - 2030 (USD Billion)
  • 7.4. Retail Pharmacies
    • 7.4.1. Global Psoriatic Arthritis Market, by Retail Pharmacies, by Region, 2018 - 2030 (USD Billion)
  • 7.5. Online Pharmacies
    • 7.5.1. Global Psoriatic Arthritis Market, by Online Pharmacies, by Region, 2018 - 2030 (USD Billion)

8. Global Psoriatic Arthritis Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Psoriatic Arthritis Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 8.3. Psoriatic Arthritis Market - North America
    • 8.3.1. North America: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.3.2. North America: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
    • 8.3.3. North America: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.3.4. Psoriatic Arthritis Market - U.S.
      • 8.3.4.1. U.S.: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.3.4.2. U.S.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.3.4.3. U.S.: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.3.5. Psoriatic Arthritis Market - Canada
      • 8.3.5.1. Canada: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.3.5.2. Canada.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.3.5.3. Canada: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • 8.4. Psoriatic Arthritis Market - Europe
    • 8.4.1. Europe: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.4.2. Europe.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
    • 8.4.3. Europe: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.4.4. Psoriatic Arthritis Market - UK
      • 8.4.4.1. UK: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.4.2. UK.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.4.4.3. UK: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.4.5. Psoriatic Arthritis Market - France
      • 8.4.5.1. France: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.5.2. France.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.4.5.3. France: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.4.6. Psoriatic Arthritis Market - Germany
      • 8.4.6.1. Germany: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.6.2. Germany.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.4.6.3. Germany: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.4.7. Psoriatic Arthritis Market - Italy
      • 8.4.7.1. Italy: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.7.2. Italy.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.4.7.3. Italy: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.4.8. Psoriatic Arthritis Market - Spain
      • 8.4.8.1. Spain: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.8.2. Spain.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.4.8.3. Spain: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.4.9. Psoriatic Arthritis Market - Netherlands
      • 8.4.9.1. Netherlands: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.9.2. Netherlands.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.4.9.3. Netherlands: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.4.10. Psoriatic Arthritis Market - Russia
      • 8.4.10.1. Russia: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.10.2. Russia.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.4.10.3. Russia: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • 8.5. Psoriatic Arthritis Market - Asia Pacific
    • 8.5.1. Asia Pacific: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.5.2. Asia Pacific.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
    • 8.5.3. Asia Pacific: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.5.4. Psoriatic Arthritis Market - China
      • 8.5.4.1. China: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.4.2. China.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.5.4.3. China: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.5.5. Psoriatic Arthritis Market - India
      • 8.5.5.1. India: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.5.2. India.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.5.5.3. India: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.5.6. Psoriatic Arthritis Market - Malaysia
      • 8.5.6.1. Malaysia: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.6.2. Malaysia.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.5.6.3. Malaysia: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.5.7. Psoriatic Arthritis Market - Japan
      • 8.5.7.1. Japan: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.7.2. Japan.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.5.7.3. Japan: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.5.8. Psoriatic Arthritis Market - Indonesia
      • 8.5.8.1. Indonesia: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.8.2. Indonesia.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.5.8.3. Indonesia: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.5.9. Psoriatic Arthritis Market - South Korea
      • 8.5.9.1. South Korea: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.9.2. South Korea.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.5.9.3. South Korea: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • 8.6. Psoriatic Arthritis Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.6.2. Middle East & Africa.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
    • 8.6.3. Middle East & Africa: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.6.4. Psoriatic Arthritis Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.6.5. Psoriatic Arthritis Market - UAE
      • 8.6.5.1. UAE: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.6.5.2. UAE.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.6.5.3. UAE: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.6.6. Psoriatic Arthritis Market - Israel
      • 8.6.6.1. Israel: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.6.6.2. Israel.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.6.6.3. Israel: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.6.7. Psoriatic Arthritis Market - South Africa
      • 8.6.7.1. South Africa: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.6.7.2. South Africa.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.6.7.3. South Africa: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • 8.7. Psoriatic Arthritis Market - Latin America
    • 8.7.1. Latin America: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.7.2. Latin America.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
    • 8.7.3. Latin America: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.7.4. Psoriatic Arthritis Market - Mexico
      • 8.7.4.1. Mexico: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.7.4.2. Mexico.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.7.4.3. Mexico: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.7.5. Psoriatic Arthritis Market - Brazil
      • 8.7.5.1. Brazil: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.7.5.2. Brazil.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.7.5.3. Brazil: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.7.6. Psoriatic Arthritis Market - Argentina
      • 8.7.6.1. Argentina: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.7.6.2. Argentina.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.7.6.3. Argentina: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AbbVie Inc
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. AstraZeneca PLC
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Amgen Inc
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Bausch Health Companies Inc
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Bristol-Myers Squibb Company
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Celgene Corp
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Eli Lilly and Company
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Johnson & Johnson Services, Inc
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Novartis International AG
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Pfizer, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. UCB S.A
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development